MET and glioblastoma: The results for VEGFR2 expression were similar to c-Met: while there was no impact on TTP-1, the TTP-2 of patients with VEGFR2-overexpressing GBM was significantly shorter than the TTP2 of patients with VEGFR2-negative GBM (3 months versus 7 months, respectively, p = 0.009).